Abstract:CD36 plays a critical role in lipid metabolism, which is closely associated with human immunity. However, the role of CD36 in cancer remains unclear. We performed a pan-cancer analysis to elucidate the potential role of CD36 in cancer by investigating its prognostic value and current predictors for the efficacy of immune checkpoint inhibitors (ICIs) in multiple cancer types. CD36 expression in cancer cell lines, tumor tissue, and their adjacent normal tissues displayed heterogeneity among different cancers. Immunohistochemistry was used to detect CD36 expression and confirmed the results. CD36 expression significantly affects prognosis in the six cancer types. High CD36 expression was marginally associated with poorer prognosis in four of them and improved prognosis in the remaining two types. CD36 expression was significantly correlated with the 6 immune infiltrates in most cancer types. In addition, CD36 gene expression was positively correlated with Stromal score, Immune score, and ESTIMATE score. A total of 47 immune checkpoint genes were collected and their relationship with CD36 expression was analyzed. CD36 expression was significantly associated with multiple stimulatory and inhibitory checkpoint molecules with a disease-specific pattern. As to the genes reported to positively relate to the efficacy of ICIs, CD36 expression was positively correlated with most of them but negatively associated with a small proportion of cancer type-specific patterns. Concerning the genes negatively related to the efficacy of ICIs, CD36 expression was positively correlated with NRP1 and TNFSF15 in multiple cancers. CD36 expression was negatively correlated with tumor neoantigen burden in most cancer types. However, CD36 expression was negatively correlated with tumor mutation burden in most cancer types. The correlation between CD36 expression and the four methyltransferases was also significant in multiple cancers, but also with a cancer type-specific pattern. In summary, the current study found CD36 expression and its prognostic value in multiple cancer types. In addition, the expression of CD36 was significantly associated with current predictors for the efficacy of ICIs. The practical application value of CD36 is disease specific.

The regulatory role of CD36 in hematopoiesis beyond fatty acid uptake

CD36 and Its Role in Regulating the Tumor Microenvironment

CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate

CD36: a promising therapeutic target in hematologic tumors

CD 36: Focus on Epigenetic and Post-Transcriptional Regulation

The function of CD36 in Mycobacterium tuberculosis infection

Ligand-dependent CD36 Functions in Cancer Progression, Metastasis, Immune Response, and Drug Resistance

Role of CD36 in central nervous system diseases

CD36 Signal Transduction in Metabolic Diseases: Novel Insights and Therapeutic Targeting

CD36 Tango in Cancer: Signaling Pathways and Functions

Interplay of CD36, autophagy, and lipid metabolism: insights into cancer progression

The Multifunctionality of CD36 in Diabetes Mellitus and Its Complications—Update in Pathogenesis, Treatment and Monitoring

Soluble Cd36 Ectodomain Binds Negatively Charged Diacylglycerol Ligands And Acts As A Co-Receptor For Tlr2

Deletion of CD36 exhibits limited impact on normal hematopoiesis and the leukemia microenvironment

CD36 Senses Dietary Lipids and Regulates Lipids Homeostasis in the Intestine

Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36

The Emerging Roles of Fatty Acid Translocase/Cd36 and the Aryl Hydrocarbon Receptor in Fatty Liver Disease

CD36: the Bridge Between Lipids and Tumors

Prognostic and immunological role of CD36: A pan-cancer analysis

CD36 in Atherosclerosis: the Role of a Class B Macrophage Scavenger Receptor

Cellular Fatty Acid Uptake: a Pathway under Construction.